47
Participants
Start Date
September 19, 2023
Primary Completion Date
August 31, 2028
Study Completion Date
August 31, 2028
External beam radiotherapy
Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B receive standard-of-care external beam radiotherapy to the brain tumor.
131I-Metaiodobenzylguanidine (MIBG)
Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B receive the radiopharmaceutical 131I-Metaiodobenzylguanidine (MIBG) 15 mCi/kg via either a central or a peripheral IV catheter over 1.5 to 2 hours at a maximum rate of 500 mCi/hour.
RECRUITING
University of California, San Francisco, San Francisco
RECRUITING
Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute
OTHER
National Cancer Institute (NCI)
NIH
University of California, San Francisco
OTHER
Brigham and Women's Hospital
OTHER